RUXOLITINIB
ruxolitinib 5 mg tablet, 56
RUXOLITINIB (10616R)
10616R
Manner of administration:Oral
Restriction (Streamlined authority code: 18324)
Indication: High risk and intermediate-2 risk myelofibrosis
Treatment phase: Continuing treatment
Restriction (Streamlined authority code: 18241)
Indication: Intermediate-1 risk myelofibrosis
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 2 | Max qty units: 112 | # of repeats: 5 | DPMQ: $4,675.44 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Jakavi | |||||